Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 42Neoplasms 17Neoplasm Metastasis 15Carcinoma, Non-Small-Cell Lung 14Breast Neoplasms 14Ovarian Neoplasms 11Triple Negative Breast Neoplasms 6Stomach Neoplasms 6Lung Neoplasms 6Melanoma 5Fallopian Tube Neoplasms 5Squamous Cell Carcinoma of Head and Neck 4Peritoneal Neoplasms 4Lymphoma, Non-Hodgkin 4Hodgkin Disease 4Carcinoma, Pancreatic Ductal 4Adenocarcinoma 4Recurrence 3Rectal Neoplasms 3Prostatic Neoplasms 3Lymphoma 3Head and Neck Neoplasms 3Gallbladder Neoplasms 3Endometrial Neoplasms 3Colorectal Neoplasms 3Urinary Bladder Neoplasms 2Unspecified Adult Solid Tumor, Protocol Specific 2Small Cell Lung Carcinoma 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Lymphoma, B-Cell 2

Interventions

pembrolizumab 1paricalcitol 1Taxes 1Gemcitabine 1Albumin-Bound Paclitaxel 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Resectable Pancreatic Carcinoma × Albumin-Bound Paclitaxel × Clear all
NCT02930902 2023-02-09

Pembrolizumab and Paricalcitol With or Without Chemotherapy in Patients With Pancreatic Cancer That Can Be Removed by Surgery

M.D. Anderson Cancer Center

Phase 1 Completed
9 enrolled
Gastrointestinal

Resectable Pancreatic Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡